Our four award-winning divisions; marketing, communications, insight & analytics and digital, drive our creativity and define our solutions. Our mission is to create genuine business advantage for clients and we do this by uncovering behaviour-led insight from our Human Understanding Lab that are critical to powering performance.
Overview
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 20, 2025 | Accenture Announced the Acquisition of Superdigital | Accenture (NYSE: ACN) has acquired Superdigital, a U.S.-based social and influencer agency. Superdigital will join Accenture Song to bolster existing client offerings in end-to-end social marketing from audience and community strategy to co... |
| Apr 11, 2024 | AbbVie’s AQUIPTA[®]▼(atogepant) Is Recommended By NICE For The Prevention Of Migraine In Adults | AbbVie’s AQUIPTA[®]▼(atogepant) Is Recommended By NICE For The Prevention Of Migraine In Adults Thu, Apr 11, 2024 08:00 CET Report this content PRESS RELEASE - For UK consumer, medical and trade media only The National Institute for Health ... |
| Oct 9, 2023 | AbbVie’s AQUIPTA[®]▼ (atogepant) Is Now Available In Scotland For The Prevention Of Migraines In Adults | AbbVie’s AQUIPTA[®]▼ (atogepant) Is Now Available In Scotland For The Prevention Of Migraines In Adults Mon, Oct 09, 2023 11:02 CET Report this content PRESS RELEASE - For UK consumer, medical and trade media only The Scottish Medicines Con... |
| Sep 4, 2023 | AbbVie’s AQUIPTA[®]▼(atogepant) receives MHRA marketing authorisation for the prevention of migraines in adults | AbbVie’s AQUIPTA[®]▼(atogepant) receives MHRA marketing authorisation for the prevention of migraines in adults Mon, Sep 04, 2023 01:05 CET Report this content PRESS RELEASE - For UK consumer, trade and medical media only The oral, once-dai... |
| Jun 29, 2022 | NICE recommends AbbVie’s RINVOQ[®▼ (upadacitinib) for use in adults and adolescents 12 years and older with moderate to severe atopic dermatitis (eczema)] | NICE recommends AbbVie’s RINVOQ[®▼ (upadacitinib) for use in adults and adolescents 12 years and older with moderate to severe atopic dermatitis (eczema)] Wed, Jun 29, 2022 12:13 CET Report this content Press release key messages: Adults an... |
Reviews 0
FAQ about UNLIMITED
When was UNLIMITED founded?
UNLIMITED was founded in 2001.
What has the press written about UNLIMITED?
Parsers VC has collected 6 articles mentioning UNLIMITED, among them “Accenture Announced the Acquisition of Superdigital” (Aug 20, 2025) and “AbbVie’s AQUIPTA[®]▼(atogepant) Is Recommended By NICE For The Prevention Of Migraine In Adults” (Apr 11, 2024).
Is UNLIMITED still active?
Yes, UNLIMITED is active; its latest activity on Parsers VC dates from Sep 8, 2025.